Dominari Holdings Inc. (NASDAQ:DOMH – Get Free Report) CEO Anthony Hayes acquired 50,000 shares of the stock in a transaction dated Thursday, September 10th. The shares were bought at an average cost of $2.02 per share, with a total value of $101,000.00. Following the completion of the purchase, the chief executive officer directly owned 4,550,873 shares in the company, valued at approximately $9,192,763.46. This trade represents a 1.11% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Dominari Stock Up 2.3%
DOMH stock opened at $2.23 on Tuesday. The company has a market cap of $54.06 million, a price-to-earnings ratio of -0.41 and a beta of 0.87. The business has a fifty day simple moving average of $2.55 and a 200-day simple moving average of $2.92. Dominari Holdings Inc. has a 52 week low of $1.91 and a 52 week high of $8.40.
Dominari (NASDAQ:DOMH – Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.13. Dominari had a negative return on equity of 235.37% and a negative net margin of 51.61%.The firm had revenue of $16.79 million for the quarter, compared to analysts’ expectations of $16.79 million.
Institutional Trading of Dominari
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dominari in a report on Monday, July 6th. Wall Street Zen lowered shares of Dominari from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.
Read Our Latest Stock Report on Dominari
About Dominari
Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.
Featured Articles
- Five stocks we like better than Dominari
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
Receive News & Ratings for Dominari Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dominari and related companies with MarketBeat.com's FREE daily email newsletter.
